Cargando…

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients

There is an urgent need to identify effective strategies to prevent leukemic transformation and induce sustained deep remissions in adult high-risk myelodysplastic syndrome (MDS) patients. This article discusses the clinical impact potential of bispecific antibodies (BiAB) capable of redirecting hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uckun, Fatih M., Watts, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Aging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261311/ https://www.ncbi.nlm.nih.gov/pubmed/35822053 http://dx.doi.org/10.3389/fragi.2021.757276

Ejemplares similares

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
por: Cheng, Pingyan, et al.
Publicado: (2022)

Interaction Mediated by the Putative Tip Regions of MdsA and MdsC in the Formation of a Salmonella-Specific Tripartite Efflux Pump
por: Song, Saemee, et al.
Publicado: (2014)

Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
por: Velegraki, Maria, et al.
Publicado: (2022)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
por: Uckun, Fatih M., et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways
por: Guerenne, Laura, et al.
Publicado: (2016)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

PS Beams for SPS MDs
por: Manglunki, Django
Publicado: (1998)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

William Jarvie, M.D.S.
Publicado: (1922)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Results of MD’s in Autumn 1988 on e+
por: Canard, B, et al.
Publicado: (1989)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Targeting the Microenvironment in MDS: The Final Frontier
por: Teodorescu, Patric, et al.
Publicado: (2020)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Stewart Bailey Palmer, M.D.S.
Publicado: (1903)

Stewart B. Palmer, M.D.S.
Publicado: (1903)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation
por: Zhao, Sida, et al.
Publicado: (2017)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer
por: Ma, Peiwen, et al.
Publicado: (2019)

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Dietary modification of myeloid-derived suppressor cells (MDSC) activity in sepsis
por: Ochoa Gautier, Juan B.
Publicado: (2022)

The Ghost Train Instability (MDs 2066 and 2936)
por: Carver, Lee Robert, et al.
Publicado: (2018)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lu50r7luf6841ql8e879j4e0op